April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Long Term Efficacy of Infliximab in the Treatment of Pediatric Uveitis
Author Affiliations & Notes
  • Mitul C. Mehta
    Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio
    Cincinnati Eye Institute, Cincinnati, Ohio
  • Sarah Lopper
    Department of Pediatric Ophthalmology,
    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
  • Daniel Ash
    Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio
  • Daniel J. Lovell
    Rheumatology,
    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
  • Adam Kaufman
    Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio
    Cincinnati Eye Institute, Cincinnati, Ohio
  • Footnotes
    Commercial Relationships  Mitul C. Mehta, None; Sarah Lopper, None; Daniel Ash, None; Daniel J. Lovell, Centocor Inc. - nonpaid consultant for study and trial design (C); Adam Kaufman, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mitul C. Mehta, Sarah Lopper, Daniel Ash, Daniel J. Lovell, Adam Kaufman; Long Term Efficacy of Infliximab in the Treatment of Pediatric Uveitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : In this study we present five pediatric patients with combined anterior and intermediate uveitis who have been well controlled on infliximab for an average of 4.2 years.

Methods: : We reviewed the ophthalmology charts of children at Cincinnati Children’s Hospital Medical Center (CCHMC) and the Uveitis service at the University of Cincinnati Department of Ophthalmology (UC) who were started on infliximab between October 1, 2002 and June 1, 2009, and identified all of the patients who remained on infliximab for greater than 2 years. Uveitis was graded according to the Standardization of Uveitis Nomenclature (SUN) Working Group classification system. A total of 9 patients met the entrance criteria, 4 had combined anterior and intermediate uveitis, 2 had juvenile idiopathic arthritis (JIA) associated anterior uveitis, and 3 had idiopathic anterior uveitis not associated with arthritis.

Results: : Four of the 9 patients were eventually switched to adalimumab. One of those patients was switched due to eventual loss of efficacy of infliximab, two patients were switched for financial reasons, and one patient was switched due to adverse effects. The remaining 5 patients, all are well controlled (1/2+ or less cell in the worse eye) on infliximab, on steroid eye drops not more than four times per day, with or without weekly methotrexate for a mean of 4.22 years with a standard deviation of 1.65 years. Four of those 5 patients were diagnosed with combined anterior and intermediate uveitis, and the other patient had only anterior uveitis associated with JIA.

Conclusions: : The potential loss of efficacy of infliximab for the treatment of uveitis has been previously described. In this series, we have shown that infliximab can be effective for long term treatment of combined anterior and intermediate uveitis in children.

Keywords: inflammation • autoimmune disease • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×